A Phase 3, open-label, randomized, multicenter study designed to evaluate the antitumor efficacy of DZD8586 compared with the investigator’s choice of therapy in patients with relapsed or refractory chronic lymphocytic leukemia or small-cell lymphocytic lymphoma.
Principal Investigator
Dott. Umberto Vitolo
Contact Information for Access
Phase
FASE III
Status
ATTIVO
Objective of the study
The objective of the study is to evaluate the clinically superior efficacy of DZD8586 therapy compared to the standard of care.
Chronic lymphocytic leukemia/Small lymphocytic lymphoma
ClinicalTrials.gov ID NCT07139873
Sponsor: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Pathologies
Onco-hematological (hematological cancers/malignancies)
Medication
DZD8586
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients diagnosed with relapsed or refractory CLL/SLL or who are intolerant to treatment with at least one BTK inhibitor.
View the full study Back to search page